RAPP
HealthcareRapport Therapeutics, Inc. Common Stock
Key Drivers
- Very high liquidity
- Zero revenue
- Heavy cash burn
AIAI Summary
RAPP has shifted from a cash‑constrained early‑stage biotech to a well‑funded, near‑registrational play—driven by RAP‑219 and a China licensing deal that materially de‑risks near‑term funding—so the investment now hinges on Phase‑3 execution and milestone capture (Tenacia) as the primary value drivers while monitoring trial/regulatory outcomes and potential dilution if timelines slip.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high liquidity
- •Zero revenue
- •Heavy cash burn
RAPP: extremely liquid balance sheet (85% liquid assets, current ratio 26.2) but zero revenue, large operating losses and negative cash flow, relying on investments/financing to fund heavy cash burn. #cash-burn #strong-balance
Price Behavior
Key Price Behavior Insights:
- •Downward momentum
- •Failed SMA retake
- •Defined short risk
Price is in a short-term downtrend: trading below the last month SMA (~$28.89), down ~11% from the mid‑March $30.54 highs to the $27.08 close, with immediate support near $26.48 and resistance at ~$28.9–$30.5.
~11% drop from $30.54 in mid‑March to $27.08 on 2026-03-20
Sentiment & News
Key News Insights:
- •Phase 3 start
- •China deal
- •Strong cash
Rapport advanced RAP‑219 toward Phase 3 with robust Phase 2a data, a Greater China partnership, $490.5M cash runway into H2 2029, and amplified investor engagement.
These coordinated moves materially de-risk the program's clinical and commercial outlook, likely supporting near-term valuation and partnering leverage
Similar Companies in Healthcare
Other companies in the same sector with AI ratings